metformin has been researched along with Atheroma in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 9.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "Metformin activates a conserved AMPK-ATF1-M2-like pathway in mouse and human macrophages, and results in highly suppressed atherogenesis in hyperlipidaemic mice via haematopoietic AMPK." | 8.02 | Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase. ( Boyle, JJ; Carling, D; Cave, L; Haskard, DO; Hyde, G; Mason, JC; Moestrup, SK; Seneviratne, A, 2021) |
| "Metformin, a first-line treatment for Type 2 diabetes, is reported to be beneficial to cardiovascular disease." | 5.62 | Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE ( Dong, Z; Feng, K; Hua, Y; Ma, C; Wu, H; Yang, S; Zhang, C; Zhang, H; Zhang, J; Zhu, Y, 2021) |
| " We hypothesized that lifestyle modification (LSM) and metformin would improve CVD indices in HIV patients with metabolic syndrome." | 5.16 | Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. ( Abbara, S; Fitch, K; Grinspoon, S; Hemphill, L; Lee, H; Michel, T; Sacks, R; Stavrou, E; Torriani, M, 2012) |
| "Metformin activates a conserved AMPK-ATF1-M2-like pathway in mouse and human macrophages, and results in highly suppressed atherogenesis in hyperlipidaemic mice via haematopoietic AMPK." | 4.02 | Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase. ( Boyle, JJ; Carling, D; Cave, L; Haskard, DO; Hyde, G; Mason, JC; Moestrup, SK; Seneviratne, A, 2021) |
| "Dyslipidemia is manageable via statin treatment, while the anti-diabetic drug metformin would prevent hyperglycemia." | 2.50 | mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. ( De Loof, H; De Meyer, GRY; Martinet, W, 2014) |
| "Metformin, a first-line treatment for Type 2 diabetes, is reported to be beneficial to cardiovascular disease." | 1.62 | Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE ( Dong, Z; Feng, K; Hua, Y; Ma, C; Wu, H; Yang, S; Zhang, C; Zhang, H; Zhang, J; Zhu, Y, 2021) |
| "Metformin functions as a stabilizer of atherosclerotic plaque to reduce acute coronary accent." | 1.48 | AMPKα inactivation destabilizes atherosclerotic plaque in streptozotocin-induced diabetic mice through AP-2α/miRNA-124 axis. ( Chen, Y; Guo, T; Liang, WJ; Shan, MR; Wang, SX; Wang, XQ; Zhang, M; Zhang, Y; Zhou, SN, 2018) |
| "Inflamed atherosclerotic plaques can be visualized by noninvasive positron emission and computed tomographic imaging with (18)F-fluorodeoxyglucose, a glucose analog, but the underlying mechanisms are poorly understood." | 1.43 | Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice. ( De Vivo, DC; Gautier, EL; Giorgetti-Peraldi, S; Guinamard, R; Ivanov, S; Sarrazy, V; Thorp, EB; Viaud, M; Westerterp, M; Yvan-Charvet, L, 2016) |
| "Inflammation has been proposed as the main cause for the high risk of atherosclerotic disease in DM II." | 1.40 | Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. ( Bengtsson, E; Björkbacka, H; Dunér, P; Edsfeldt, A; Gonçalves, I; Grufman, H; Melander, O; Mollet, IG; Nilsson, J; Nilsson, M; Nitulescu, M; Orho-Melander, M; Persson, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seneviratne, A | 1 |
| Cave, L | 1 |
| Hyde, G | 1 |
| Moestrup, SK | 1 |
| Carling, D | 1 |
| Mason, JC | 1 |
| Haskard, DO | 1 |
| Boyle, JJ | 1 |
| Hu, DJ | 1 |
| Li, ZY | 1 |
| Zhu, YT | 1 |
| Li, CC | 1 |
| Wu, H | 1 |
| Feng, K | 1 |
| Zhang, C | 1 |
| Zhang, H | 1 |
| Zhang, J | 1 |
| Hua, Y | 1 |
| Dong, Z | 1 |
| Zhu, Y | 1 |
| Yang, S | 1 |
| Ma, C | 1 |
| Luo, F | 2 |
| Guo, Y | 2 |
| Ruan, GY | 1 |
| Long, JK | 1 |
| Zheng, XL | 1 |
| Xia, Q | 1 |
| Zhao, SP | 1 |
| Peng, DQ | 1 |
| Fang, ZF | 1 |
| Li, XP | 1 |
| Liang, WJ | 1 |
| Zhou, SN | 1 |
| Shan, MR | 1 |
| Wang, XQ | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Zhang, Y | 1 |
| Wang, SX | 1 |
| Guo, T | 1 |
| Martinet, W | 1 |
| De Loof, H | 1 |
| De Meyer, GRY | 1 |
| Edsfeldt, A | 1 |
| Gonçalves, I | 1 |
| Grufman, H | 1 |
| Nitulescu, M | 1 |
| Dunér, P | 1 |
| Bengtsson, E | 1 |
| Mollet, IG | 1 |
| Persson, A | 1 |
| Nilsson, M | 1 |
| Orho-Melander, M | 1 |
| Melander, O | 1 |
| Björkbacka, H | 1 |
| Nilsson, J | 1 |
| Sarrazy, V | 1 |
| Viaud, M | 1 |
| Westerterp, M | 1 |
| Ivanov, S | 1 |
| Giorgetti-Peraldi, S | 1 |
| Guinamard, R | 1 |
| Gautier, EL | 1 |
| Thorp, EB | 1 |
| De Vivo, DC | 1 |
| Yvan-Charvet, L | 1 |
| Ruan, G | 1 |
| Li, X | 1 |
| Fitch, K | 1 |
| Abbara, S | 1 |
| Lee, H | 1 |
| Stavrou, E | 1 |
| Sacks, R | 1 |
| Michel, T | 1 |
| Hemphill, L | 1 |
| Torriani, M | 1 |
| Grinspoon, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Strategies for the Treatment of HIV Associated Metabolic Syndrome[NCT00399360] | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Abdominal visceral adipose area was assess by magnetic resonance imaging at the lvel of the L4 pedicle. The change in abdominal visceral adiposity between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm2 (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -22.6 |
| Lifestyle Modification and Placebo | -1.5 |
| No Lifestyle Modification and Metformin | -28.2 |
| Lifestyle Modification and Metformin | -35.0 |
High sensitivity C-reactive protein was determined by R&D Systems (Minneapolis, MN) kit. The change in C-reactive protein between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/l (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.27 |
| Lifestyle Modification and Placebo | -1.19 |
| No Lifestyle Modification and Metformin | 0.47 |
| Lifestyle Modification and Metformin | -1.92 |
A submaximal exercise stress test was conducted on a cycle ergometer to measure endurance. Subjects cycled between 50-60 revolutions per minute and the workload was progressively increased in increments of 50 watts in stages lasting 3 minutes. Once subjects became fatigued or reached their submaximal heart rate (220-age x 85), the test was stopped and separate readings of heart rate and blood pressure were measured at 1, 3, and 5 min of recovery. Weight-adjusted maximum oxygen consumption (VO2max; ml/kg per minute) was determined. The change in cardiorespiratory fitness between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | ml/kg/min (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.7 |
| Lifestyle Modification and Placebo | 2.0 |
| No Lifestyle Modification and Metformin | -1.3 |
| Lifestyle Modification and Metformin | 3.7 |
Carotid intima media thickness imaging of the common carotid artery was conducted using a high-resolution 7.5-MHz phased-array transducer (SONOS 2000/2500. The change of the carotid intima media thickness measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -0.02 |
| Lifestyle Modification and Placebo | -0.02 |
| No Lifestyle Modification and Metformin | 0.00 |
| Lifestyle Modification and Metformin | 0.03 |
Computed tomography (CT) imaging was performed using a SOMATOM Sensation (Siemens Medical Solutions, Forcheim, Germany) 64-slice CT scanner. Agatston calcium score was calculated using CT images. The total Agatston score is calculated by summing up the scores of the individual calcifications in all slices of the CT scan. An absolute Agatston score of less than 10 indicates minimal overall atherosclerosis (plaques) in the coronary arteries. The change in the coronary artery calcium score between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | Agatston score (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 43 |
| Lifestyle Modification and Placebo | 19 |
| No Lifestyle Modification and Metformin | 1 |
| Lifestyle Modification and Metformin | -4 |
Glucose level was determined after an overnight fast. The change in glucose between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -7 |
| Lifestyle Modification and Placebo | 3 |
| No Lifestyle Modification and Metformin | 2 |
| Lifestyle Modification and Metformin | -7 |
High density lipoprotein (HDL) was determined after an overnight fast. The change in HDL between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -2 |
| Lifestyle Modification and Placebo | 2 |
| No Lifestyle Modification and Metformin | 0 |
| Lifestyle Modification and Metformin | 4 |
Intramyocellular lipid (IMCL) of the tibialis anterior was determined using 1H-magnetic resonance spectroscopy (Siemens, Munich, Germany). The change in the intramyocellular lipid measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mmol/kg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | 0.6 |
| Lifestyle Modification and Placebo | -0.4 |
| No Lifestyle Modification and Metformin | 0.8 |
| Lifestyle Modification and Metformin | 0.1 |
Systolic blood pressure was measured after 5 minutes rest. The in systolic blood pressure between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -5 |
| Lifestyle Modification and Placebo | -2 |
| No Lifestyle Modification and Metformin | -2 |
| Lifestyle Modification and Metformin | -6 |
Iliac waist circumference measurements were obtained using an inelastic tape measure. All measurements were obtained in triplicate, with the patient undressed, and then averaged. The change of the waist circumference measurement between baseline and 12 months is reported. (NCT00399360)
Timeframe: baseline and 12 months
| Intervention | cm (Mean) |
|---|---|
| No Lifestyle Modification and Placebo | -1.9 |
| Lifestyle Modification and Placebo | -0.1 |
| No Lifestyle Modification and Metformin | 0.3 |
| Lifestyle Modification and Metformin | -1.4 |
1 review available for metformin and Atheroma
| Article | Year |
|---|---|
mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.
Topics: Absorbable Implants; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Cholesterol; Clinica | 2014 |
1 trial available for metformin and Atheroma
| Article | Year |
|---|---|
Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome.
Topics: Adolescent; Adult; Aged; Atherosclerosis; Female; HIV Infections; Humans; Hypoglycemic Agents; Life | 2012 |
8 other studies available for metformin and Atheroma
| Article | Year |
|---|---|
Metformin directly suppresses atherosclerosis in normoglycaemic mice via haematopoietic adenosine monophosphate-activated protein kinase.
Topics: Activating Transcription Factor 1; AMP-Activated Protein Kinases; Animals; Aorta; Aortic Diseases; A | 2021 |
Overexpression of long noncoding RNA ANRIL inhibits phenotypic switching of vascular smooth muscle cells to prevent atherosclerotic plaque development
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Female; Humans; Male; Metformin; Mice; Middle A | 2020 |
Metformin attenuates atherosclerosis and plaque vulnerability by upregulating KLF2-mediated autophagy in apoE
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Autophagy; Cholesterol; Diet, High-Fa | 2021 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Mod | 2017 |
AMPKα inactivation destabilizes atherosclerotic plaque in streptozotocin-induced diabetic mice through AP-2α/miRNA-124 axis.
Topics: AMP-Activated Protein Kinases; Animals; Collagen Type I; Collagen Type II; Diabetes Mellitus, Experi | 2018 |
Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Topics: Aged; Antihypertensive Agents; Carotid Artery Diseases; Cytokines; Diabetes Mellitus, Type 2; Diseas | 2014 |
Disruption of Glut1 in Hematopoietic Stem Cells Prevents Myelopoiesis and Enhanced Glucose Flux in Atheromatous Plaques of ApoE(-/-) Mice.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Bone Marrow Transplantation; Cell Division; Cytokine Re | 2016 |
Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism.
Topics: Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transpor | 2016 |